Fintel reports that on September 5, 2025, Craig-Hallum initiated coverage of Immunome (NasdaqCM:IMNM) with a Buy recommendation.

Analyst Price Forecast Suggests 129.84% Upside

As of September 3, 2025, the average one-year price target for Immunome is $24.22/share. The forecasts range from a low of $18.18 to a high of $39.90. The average price target represents an increase of 129.84% from its latest reported closing price of $10.54 / share.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Immunome is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is 6.55.

What is the Fund Sentiment?

There are 293 funds or institutions reporting positions in Immunome. This is an increase of 2 owner(s) or 0.69% in the last quarter. Average portfolio weight of all funds dedicated to IMNM is 0.18%, an increase of 14.60%. Total shares owned by institutions increased in the last three months by 2.48% to 87,875K shares. The put/call ratio of IMNM is 0.51, indicating a bullish outlook.

What are Other Shareholders Doing?

T. Rowe Price Investment Management holds 8,275K shares representing 9.51% ownership of the company. In its prior filing, the firm reported owning 7,555K shares , representing an increase of 8.71%. The firm increased its portfolio allocation in IMNM by 44.49% over the last quarter.

Redmile Group holds 4,872K shares representing 5.60% ownership of the company. In its prior filing, the firm reported owning 5,361K shares , representing a decrease of 10.04%. The firm increased its portfolio allocation in IMNM by 41.41% over the last quarter.

Enavate Sciences GP holds 4,769K shares representing 5.48% ownership of the company. No change in the last quarter.

Point72 Asset Management holds 4,686K shares representing 5.38% ownership of the company. In its prior filing, the firm reported owning 4,361K shares , representing an increase of 6.94%. The firm increased its portfolio allocation in IMNM by 27.69% over the last quarter.

EcoR1 Capital holds 4,079K shares representing 4.69% ownership of the company. No change in the last quarter.